<DOC>
	<DOC>NCT00415363</DOC>
	<brief_summary>This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer. Approximately 108 patients will be randomly assigned to receive either enzastaurin or placebo after having completed whole brain radiotherapy.</brief_summary>
	<brief_title>Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Having radiologically proven brain metastases of lung cancer Having received whole brain radiotherapy with either 30 grays in 2 weeks or 20 grays in one week. Treatment with enzastaurin must start within 14 days after the last fraction of the whole brain radiotherapy No other previous radiotherapy to the brain except for radiosurgery at one occasion Adequate organ function as measured by appropriate laboratory tests. Age 18 years or older. Inability to swallow tablets or show conditions which could interfere with oral medication intake (e.g. vomiting, partial bowel obstruction). Inability to discontinue use of certain antiepileptic drugs such as, carbamazepine, phenobarbital or phenytoin. Concurrent administration of warfarin Hemophilia Having had any systemic anticancer treatment within the last 2 weeks prior to enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>